HSBC says this biopharma company can jump 25% despite 'patent cliff'

  • 📰 CNBC
  • ⏱ Reading Time:
  • 5 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 5%
  • Publisher: 72%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

HSBC initiated coverage on the drug treatment developer with a buy rating.

Its price target of $320 suggests shares could rally 25% from Tuesday's close. "Amgen is a best-in-class operator with high margins and a strong history of protecting its assets. While some very old products are finally facing patent cliffs it will likely be gradual and a broadened portfolio allows for continued growth," analyst Morten Herholdt wrote in a Wednesday note.

mountain AMGN in 2023 — CNBC's Michael Bloom contributed to this report.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 12. in BR

Brasil Últimas Notícias, Brasil Manchetes